Hinge Health, Inc. (HNGE)
| Market Cap | 9.34B +162.4% |
| Revenue (ttm) | 800.82M +49.9% |
| Net Income | 374.61M |
| EPS | 1.99 |
| Shares Out | 80.69M |
| PE Ratio | 58.26 |
| Forward PE | 39.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,540,717 |
| Open | 116.51 |
| Previous Close | 115.98 |
| Day's Range | 111.00 - 118.70 |
| 52-Week Range | 30.08 - 124.94 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 135.38 (+16.95%) |
| Earnings Date | Nov 2, 2026 |
About HNGE
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, C... [Read more]
Financial Performance
In 2025, Hinge Health's revenue was $587.86 million, an increase of 50.58% compared to the previous year's $390.40 million. Losses were -$424.09 million, 3453.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for HNGE stock is "Buy." The 12-month stock price target is $135.38, which is an increase of 16.95% from the latest price.
News
Hinge Health price target raised to $138 from $92 at Raymond James
Raymond James raised the firm’s price target on Hinge Health (HNGE) to $138 from $92 and keeps an Outperform rating on the shares. The company delivered another quarter of 50%+…
Hinge Health price target raised to $135 from $110 at RBC Capital
RBC Capital raised the firm’s price target on Hinge Health (HNGE) to $135 from $110 and keeps an Outperform rating on the shares. The company delivered another strong quarter of…
Hinge Health price target raised to $135 from $103 at Freedom Capital
Freedom Capital analyst Gene Mannheimer raised the firm’s price target on Hinge Health (HNGE) to $135 from $103 and keeps a Buy rating on the shares. The company’s Q3 results…
Hinge Health price target raised to $134 from $105 at Canaccord
Canaccord analyst Richard Close raised the firm’s price target on Hinge Health (HNGE) to $134 from $105 and keeps a Buy rating on the shares. The firm said Hinge Health…
Hinge Health price target raised to $135 from $130 at Stifel
Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $135 from $130 and keeps a Buy rating on the shares.
Hinge Health price target raised to $132 from $103 at Wells Fargo
Wells Fargo raised the firm’s price target on Hinge Health (HNGE) to $132 from $103 and keeps an Overweight rating on the shares following quarterly results. Verbal lives already top…
Hinge Health price target raised to $131 from $117 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Hinge Health (HNGE) to $131 from $117 and keeps an Overweight rating on the shares. The firm, which sees “no letup in…
Hinge Health Earnings Call Transcript: Q3 2026
Q3 revenue grew 52% YoY to $235M, with 33% operating margin and $120M adjusted free cash flow. FY 2026 guidance rose as stronger yield and eligible lives supported growth; MSK remains core while Migraine and GI expand the platform.
Hinge Health Earnings release: Q3 2026
Hinge Health released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Hinge Health Slides: Q3 2026
Hinge Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Hinge Health Prepared remarks: Q3 2026
Hinge Health filed a regulatory document on November 2, 2026 disclosing important business information.
Hinge Health reports Q3 EPS 66c, consensus 60c
Reports Q3 revenue $235M, consensus $223.78M. “Our strong performance continues to reflect our ability to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs a...
Hinge Health sees FY26 revenue $879M-$881M, consensus $860.61M
“We are raising our non-GAAP income from operations guidance to be between $266 million and $268 million, reflecting year-over-year growth of 123% and non-GAAP operating margin of 30% at the…
Hinge Health sees Q4 revenue $249M-$251, consensus $239.6M
“We expect non-GAAP income from operations to be between $81 million and $83 million, reflecting year-over-year growth of 71% and non-GAAP operating margin of 33% at the midpoint, a ~470…
Hinge Health reports record third quarter 2026 financial results
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2026 and provided a business update. “Our strong performance...
Hinge Health price target raised to $130 from $115 at Stifel
Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $130 from $115 and keeps a Buy rating on the shares.
Hinge Health price target raised to $130 from $110 at BofA
BofA raised the firm’s price target on Hinge Health (HNGE) to $130 from $110 and keeps a Buy rating on the shares. The firm, while updating price target for eight…
Hinge Health price target raised to $140 from $125 at KeyBanc
KeyBanc raised the firm’s price target on Hinge Health (HNGE) to $140 from $125 and keeps an Overweight rating on the shares. Into the setup for Q3 earnings, the firm…
Hinge Health price target raised to $110 from $100 at Barclays
Barclays analyst Saket Kalia raised the firm’s price target on Hinge Health (HNGE) to $110 from $100 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Hinge Health to announce third quarter 2026 financial results on November 2, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended September 30, 2026, after the U.S. financial markets clo...
Hinge Health reinstated with a Buy at BofA
BofA reinstated coverage of Hinge Health (HNGE) with a Buy rating and $110 price target The firm views Hinge as a “rare example of a high-growth vertical software company” with…
Hinge Health price target raised to $90 from $85 at Baird
Baird raised the firm’s price target on Hinge Health (HNGE) to $90 from $85 and keeps a Neutral rating on the shares following the company’s presentation at the firm’s healthcare…
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Hinge Health price target raised to $115 from $96 at Stifel
Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $115 from $96 and keeps a Buy rating on the shares. Recently investor meetings with Hinge…
Hinge Health management to meet with KeyBanc
Meeting to be held in Boston on September 10 hosted by KeyBanc.